Stockscreener 앱 받기
30.34
2.35%
-0.73
시간 외 거래:
30.34
전일 마감가:
$31.07
열려 있는:
$30.56
하루 거래량:
557.70K
Relative Volume:
0.62
시가총액:
$1.73B
수익:
$199.89M
순이익/손실:
$52.48M
주가수익비율:
35.69
EPS:
0.85
순현금흐름:
$61.15M
1주 성능:
+2.99%
1개월 성능:
-4.65%
6개월 성능:
+135.74%
1년 성능:
+176.07%
1일 변동 폭
$29.96
$31.07
1주일 범위
$28.81
$31.75
52주 변동 폭
$5.35
$38.69
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
STOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
30.34 | 1.77B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 재개 | Chardan Capital Markets | Buy |
| 2025-07-18 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Sentiment Watch: Should I hold or sell Stoke Therapeutics Inc nowJuly 2025 Opening Moves & Weekly Breakout Watchlists - baoquankhu1.vn
Commit To Buy Stoke Therapeutics At $20, Earn 20.2% Annualized Using Options - Nasdaq
Stoke Therapeutics, Inc. (STOK) Investor Outlook: A Promising 27.53% Upside Potential In Biotech - DirectorsTalk Interviews
Stoke Therapeutics (NASDAQ:STOK) Trading 6.2% HigherHere's What Happened - MarketBeat
Stoke Therapeutics Expands with New Long-Term Waltham Headquarters - TipRanks
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - Finviz
Huge Waltham lab lease fuels work on potential Dravet syndrome drug - Stock Titan
Stoke Therapeutics Shares Face Pressure from Strategic Expansion - AD HOC NEWS
Understanding Momentum Shifts in (STOK) - Stock Traders Daily
Should value investors consider Stoke Therapeutics Inc2025 Volatility Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Stoke Therapeutics (STOK) Stock Analysis: Unveiling Growth Potential with a 23.54% Upside - DirectorsTalk Interviews
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Stoke Therapeutics, Inc. $STOK is Skorpios Trust's Largest Position - MarketBeat
Trial testing breakthrough Dravet drug zorevunersen now nearly full - Dravet Syndrome News
Stoke Therapeutics (STOK) price target increased by 10.42% to 36.46 - MSN
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (STOK) Movement - Stock Traders Daily
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity (NASDAQ:STOK) - Seeking Alpha
Stoke Therapeutics (STOK) Price Target Increased by 10.42% to 36.46 - Nasdaq
STOK: Phase III for Dravet therapy nears full enrollment, with durable efficacy and regulatory momentum - TradingView — Track All Markets
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownHere's What Happened - MarketBeat
Stoke Therapeutics stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
Stoke Therapeutics stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
Phase III update Stokes hope; Dravet game-change Encoded? - BioWorld MedTech
Wedbush Raises Price Target for Stoke Therapeutics (STOK) to $36 - GuruFocus
Stoke Therapeutics Says US FDA Seeks Additional Information for Zorevunersen in Dravet Syndrome; Shares Fall - marketscreener.com
Stoke Therapeutics stock falls after delayed Phase 3 readout timeline By Investing.com - Investing.com Nigeria
Stoke Therapeutics stock falls after delayed Phase 3 readout timeline - Investing.com
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $36.00 at Wedbush - MarketBeat
8 Analysts Have This To Say About Stoke Therapeutics - Benzinga
Stoke Therapeutics (NASDAQ: STOK) sees cash runway into 2028 operations - Stock Titan
Some Analysts Just Cut Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Estimates - 富途资讯
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome - The AI Journal
Stoke Therapeutics Targets Mid-2027 Phase 3 Readout To Support FDA Filing Of Zorevunersen - Nasdaq
Biogen (BIIB) Advances with Zorevunersen Development Program - GuruFocus
Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen - TradingView — Track All Markets
Stoke Therapeutics, Inc. (STOK) Stock Analysis: Strong Buy Ratings Amid Impressive Revenue Growth and Promising Pipeline - DirectorsTalk Interviews
Why hedge funds are buying Stoke Therapeutics Inc. stockGrip and Outsole Review & size guide reminders to avoid returns - ulpravda.ru
Will Stoke Therapeutics Inc. stock gain from strong economyJuly 2025 Trends & Verified Short-Term Trading Plans - Улправда
Is Stoke Therapeutics Inc. stock a buy in volatile marketsQuarterly Market Review & Fast Gaining Stock Strategy Reports - Улправда
Fed Meeting: Is Stoke Therapeutics Inc. stock vulnerable to regulatory risksMarket Sentiment Report & Weekly High Return Stock Opportunities - ulpravda.ru
Will Stoke Therapeutics Inc. stock split again soonVolume Spike & Technical Buy Zone Confirmations - ulpravda.ru
Breakouts Watch: Will Stoke Therapeutics Inc. stock gain from strong economyQuarterly Portfolio Report & Safe Capital Growth Trade Ideas - ulpravda.ru
EBIT per share of Stoke Therapeutics, Inc. – MUN:0GT - TradingView — Track All Markets
Los Angeles Daily NewsStoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Tangible book value per share of Stoke Therapeutics, Inc. – DUS:0GT - TradingView — Track All Markets
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Cantor Fitzgerald reiterates Overweight rating on Stoke Therapeutics stock By Investing.com - Investing.com Canada
Stoke Therapeutics (STOK): New Analyst Price Target Raises to $3 - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Chardan Capital - MarketBeat
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
자본화:
|
볼륨(24시간):